FDA Warning Letter

FDA Issues Warning Letter to Happiest Baby Over SNOO Smart Sleeper Modifications and Quality System Deficiencies

The U.S. Food and Drug Administration has issued a Warning Letter to Happiest Baby, Inc., manufacturer of the SNOO Smart Sleeper, citing unapproved device modifications, intended use changes, complaint handling deficiencies, design control violations, CAPA failures, and correction-and-removal reporting violations.

The June 15, 2026 Warning Letter follows an FDA inspection of the company’s Los Angeles facility and focuses on both regulatory authorization issues and Quality System Regulation deficiencies associated with the firm’s popular infant sleep products.

FDA Challenges Changes to Authorized Device

One of FDA’s primary concerns involves Happiest Baby’s introduction of new X-Small and X-Large versions of its SNOO Sleep Sack without submitting a new premarket submission.

According to FDA, the SNOO Smart Sleeper was originally authorized through the De Novo pathway with three sleep sack sizes:

• Small (5–12 lbs)
• Medium (12–18 lbs)
• Large (18–25 lbs)

The company later introduced:

• X-Small (4–8 lbs)
• X-Large (23–25 lbs)

without obtaining additional FDA authorization.

FDA concluded that these changes could significantly affect safety and effectiveness because the altered dimensions introduced new risks involving respiratory compromise, suffocation, improper securement, and infant positioning.

The agency also noted that the X-Small sleep sack expanded use into a lower-weight population that may include more premature infants, creating a different risk profile than originally reviewed during De Novo authorization.

Hospital Expansion Draws Regulatory Scrutiny

FDA also challenged Happiest Baby’s introduction of the SNOO Hospital Bundle. The original De Novo authorization specifically identified the SNOO Smart Sleeper as a device intended for home use by caregivers.

However, FDA found that the company subsequently marketed the device to hospitals, including neonatal intensive care units (NICUs), through its SNOO Hospital Bundle product offering.

The agency determined that hospital use represents a significant change in intended use because hospital environments present different cleaning and infection-control requirements; hospitalized infants may have different medical conditions and vulnerabilities, and the addition of a wheeled mobility cart introduces new risks involving movement, tipping, instability, and transport.

FDA therefore concluded that additional premarket review was required before marketing the device for hospital use.

Complaint Handling System Criticized

Beyond premarket issues, FDA identified multiple quality system deficiencies. One of the most significant findings involved complaint handling.

According to FDA, the company routinely grouped multiple customer complaints into a single complaint investigation, potentially limiting the evaluation of individual safety concerns and Medical Device Reporting (MDR) determinations.

Examples cited by FDA included reports of mold on mattresses and mattress covers, reports that sleep sacks were too large for infants, and customer concerns involving possible choking hazards and infant positioning issues.

FDA concluded that complaint investigations were not always adequately documented and that individual complaints were not consistently evaluated on their own merits.

Design Control and Validation Deficiencies

The Warning Letter also contains extensive criticism of Happiest Baby’s design control process.

FDA alleges the company failed to conduct appropriate design validation when introducing the X-Small and X-Large sleep sacks. Instead, it relied on previous testing rather than evaluating risks associated with the modified designs.

In addition, the company did not adequately validate use conditions across the full intended infant weight range and failed to adequately validate use of SNOO Leg Lifters with the currently marketed device configuration.

The agency repeatedly emphasized that design modifications require documented impact assessments, verification activities, and validation efforts commensurate with the risks introduced by the change.

CAPA and Supplier Oversight Concerns

FDA also cited CAPA deficiencies involving recurring complaints and refurbishment activities.

In one example, customer complaints revealed that refurbished SNOO devices were being delivered with stains, bodily-fluid contamination, and unsanitary conditions.

FDA noted that the company inspected a sample of refurbished units and found all evaluated devices failed to meet quality standards. Despite this finding, FDA stated that Happiest Baby did not open an appropriate CAPA investigation to determine root causes and prevent recurrence.

Corrections and Removals Reporting Violation

FDA additionally concluded that the company’s replacement of contaminated refurbished devices constituted a reportable correction or removal under 21 CFR Part 806.

The agency stated that Happiest Baby failed to report these actions to FDA within the required timeframe.

Why This Matters

Although the products involved are infant sleep devices rather than traditional high-risk medical technologies, the Warning Letter addresses some of the most fundamental principles of medical device regulation. Design controls, complaint handling, CAPA, risk management, premarket change assessment, intended use determinations, and reporting of corrections and removals.

MDP Regulatory Intelligence Perspective

The Warning Letter may be one of the clearest recent examples of FDA reinforcing a principle that applies to manufacturers of every device type. Companies do not get to decide unilaterally that a design change is insignificant simply because it appears minor.

A few centimeters added or removed from a sleep sack, a new patient population, a new clinical setting, or a new accessory can fundamentally alter a device’s risk profile and regulatory status.

The agency’s message is straightforward. If a modification changes risk, intended use, patient population, use environment, or safety assumptions, manufacturers must conduct and document a robust regulatory and design-control assessment before commercializing the change.

For organizations implementing QMSR-compliant quality systems, this Warning Letter serves as a valuable reminder that design controls, complaint handling, CAPA, and risk management are expected to function as an integrated system, and FDA continues to evaluate them that way.

Links

Read the FDA’s announcement here.